Study treatment
PD, death
ADVERSE EVENTS, DISEASE
Patients received cabozantinib 60 mg once daily orally in the fasted state. Treatment was continued if patients showed clinical benefits or until there were any reasons for treatment discontinuation, including death, adverse events (AEs), clinical deterioration, or a second determination of progressive disease (PD). Dose modifications were permitted for managing AEs with two reduced dose levels (40 mg and 20 mg).